CagriSema is an investigational fixed-dose combination of a long-acting amylin analogue, cagrilintide 2.4 mg, and semaglutide 2.4 mg
Kario K, Okada K, Kato M, Nishizawa M, Yoshida T, Asano T, et al
The BALANCE model has been delayed indefinitely , and the GLP-1 Bridge Program has been extended through 2027 in its place
Spencer Nadolsky is an obesity and lipid specialist and founder of Vineyard Health Melynda Barnes, MD is a board-certified facial plastic surgeon and obesity medicine specialist and chief medical officer at Ro Sonia Gibson, MD is a board-certified endocrinologist and physician lead at Allara Health Who Is a Good Candidate for the GLP-1 Pill
The side effects of Hims weight-loss medications include nausea, fatigue, constipation, diarrhea, and digestive changes
Increasing water intake is crucial because it gives osmotic laxatives like Miralax the fluid they need to pull into the colon to soften the stool effectively